Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 155

Similar articles for PubMed (Select 21196489)

1.

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.

Vandekerckhove L, Verhofstede C, Demecheleer E, De Wit S, Florence E, Fransen K, Moutschen M, Mostmans W, Kabeya K, Mackie N, Plum J, Vaira D, Van Baelen K, Vandenbroucke I, Van Eygen V, Van Marck H, Vogelaers D, Geretti AM, Stuyver LJ.

J Antimicrob Chemother. 2011 Feb;66(2):265-72. doi: 10.1093/jac/dkq458. Epub 2010 Dec 31.

2.

A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients.

Kagan RM, Johnson EP, Siaw M, Biswas P, Chapman DS, Su Z, Platt JL, Pesano RL.

PLoS One. 2012;7(9):e46334. doi: 10.1371/journal.pone.0046334. Epub 2012 Sep 27.

3.

Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.

Recordon-Pinson P, Soulié C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Macé M, Ferré V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B; ANRS AC11 Resistance Study Group.

Antimicrob Agents Chemother. 2010 Aug;54(8):3335-40. doi: 10.1128/AAC.00148-10. Epub 2010 Jun 7.

4.

Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.

Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Jensen MA, Thielen A, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

J Infect Dis. 2011 Jan 15;203(2):237-45. doi: 10.1093/infdis/jiq030.

5.

HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.

Svicher V, Balestra E, Cento V, Sarmati L, Dori L, Vandenbroucke I, D'Arrigo R, Buonomini AR, Van Marck H, Surdo M, Saccomandi P, Mostmans W, Aerssens J, Aquaro S, Stuyver LJ, Andreoni M, Ceccherini-Silberstein F, Perno CF.

Antiviral Res. 2011 Apr;90(1):42-53. doi: 10.1016/j.antiviral.2011.02.005. Epub 2011 Feb 22.

PMID:
21349294
6.

Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism.

Weber J, Vazquez AC, Winner D, Gibson RM, Rhea AM, Rose JD, Wylie D, Henry K, Wright A, King K, Archer J, Poveda E, Soriano V, Robertson DL, Olivo PD, Arts EJ, Quiñones-Mateu ME.

J Clin Microbiol. 2013 May;51(5):1517-27. doi: 10.1128/JCM.00092-13. Epub 2013 Mar 13.

7.

Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.

Surdo M, Balestra E, Saccomandi P, Di Santo F, Montano M, Di Carlo D, Sarmati L, Aquaro S, Andreoni M, Svicher V, Perno CF, Ceccherini-Silberstein F.

PLoS One. 2013 Jul 9;8(7):e68076. doi: 10.1371/journal.pone.0068076. Print 2013.

8.

Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.

McGovern RA, Symons J, Poon AF, Harrigan PR, van Lelyveld SF, Hoepelman AI, van Ham PM, Dong W, Wensing AM, Nijhuis M.

J Antimicrob Chemother. 2013 Sep;68(9):2007-14. doi: 10.1093/jac/dkt153. Epub 2013 May 14.

9.

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.

Symons J, van Lelyveld SF, Hoepelman AI, van Ham PM, de Jong D, Wensing AM, Nijhuis M.

J Antimicrob Chemother. 2011 Apr;66(4):890-5. doi: 10.1093/jac/dkq535. Epub 2011 Jan 28.

10.

Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.

Swenson LC, Chui CK, Brumme CJ, Chan D, Woods CK, Mo T, Dong W, Chapman D, Lewis M, Demarest JF, James I, Portsmouth S, Goodrich J, Heera J, Valdez H, Harrigan PR.

Antimicrob Agents Chemother. 2013 Dec;57(12):6122-30. doi: 10.1128/AAC.01534-13. Epub 2013 Sep 30.

11.

Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists.

Poveda E, Alcamí J, Paredes R, Córdoba J, Gutiérrez F, Llibre JM, Delgado R, Pulido F, Iribarren JA, García Deltoro M, Hernández Quero J, Moreno S, García F.

AIDS Rev. 2010 Jul-Sep;12(3):135-48. Review.

PMID:
20842202
12.

Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.

Bon I, Clò A, Borderi M, Colangeli V, Calza L, Morini S, Miserocchi A, Cricca M, Gibellini D, Re MC.

Int J Infect Dis. 2013 Oct;17(10):e875-82. doi: 10.1016/j.ijid.2013.02.020. Epub 2013 Apr 15.

13.

Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.

Baroncelli S, Galluzzo CM, Weimer LE, Pirillo MF, Volpe A, Mercuri A, Cavalli A, Fragola V, Monno L, Degli Antoni A, Ladisa N, Francisci D, Bucciardini R, Floridia M.

J Antimicrob Chemother. 2012 Jun;67(6):1479-85. doi: 10.1093/jac/dks055. Epub 2012 Feb 23.

14.

Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies.

McGovern RA, Thielen A, Mo T, Dong W, Woods CK, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

AIDS. 2010 Oct 23;24(16):2517-25. doi: 10.1097/QAD.0b013e32833e6cfb.

PMID:
20736814
15.

Determination of HIV tropism and its use in the clinical practice.

Pérez-Olmeda M, Alcami J.

Expert Rev Anti Infect Ther. 2013 Dec;11(12):1291-302. doi: 10.1586/14787210.2013.852469. Epub 2013 Nov 6. Review.

PMID:
24191978
16.

Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.

Poveda E, Paredes R, Moreno S, Alcamí J, Córdoba J, Delgado R, Gutiérrez F, Llibre JM, García Deltoro M, Hernández-Quero J, Pulido F, Iribarren JA, García F.

AIDS Rev. 2012 Jul-Sep;14(3):208-17. Review.

PMID:
22833064
17.

[Methods for determination of HIV tropism and their clinical use].

Gutiérrez F, Rodríguez JC, García F, Poveda E.

Enferm Infecc Microbiol Clin. 2011 Dec;29 Suppl 5:45-50. doi: 10.1016/S0213-005X(11)70043-X. Review. Spanish.

PMID:
22305669
18.

Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.

Swenson LC, Dong WW, Mo T, Demarest J, Chapman D, Ellery S, Heera J, Valdez H, Poon AF, Harrigan PR.

Clin Infect Dis. 2013 Jun;56(11):1659-66. doi: 10.1093/cid/cit105. Epub 2013 Feb 21.

19.

Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially.

Thielen A, Lengauer T, Swenson LC, Dong WW, McGovern RA, Lewis M, James I, Heera J, Valdez H, Harrigan PR.

Antivir Ther. 2011;16(3):319-28. doi: 10.3851/IMP1769.

PMID:
21555814
20.

Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.

Baatz F, Struck D, Lemaire M, De Landtsheer S, Servais JY, Arendt V, Schmit JC, Perez Bercoff D.

Antiviral Res. 2011 Dec;92(3):488-92. doi: 10.1016/j.antiviral.2011.10.003. Epub 2011 Oct 13.

PMID:
22020304
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk